GPT and fibrosis: A significant proportion of adults tested positive for HBsAg are initially not recommended for antiviral treatment according to the AASLD clinical practice guidelines because they have HBeAg negative inactive CHB (anti-HBe positive, persistently normal ALT, HBV DNA < 2,000 IU/mL, and with no or minimal liver necroinflammation or fibrosis) or HBeAg positive immune tolerant HBV infection (normal or minimally elevated ALT, very high HBV DNA, and minimal liver inflammation and no fibrosis) [4].